Company intelligence / Profile preview

ThinkCyte

Ownership: Private
Development stage: Commercial

Overview

ThinkCyte develops and commercializes advanced AI-driven cell analysis and sorting platforms that enable high-throughput, label-free single-cell profiling. Their technologies are used by leading biopharmaceutical companies and academic institutions for drug discovery, disease research, diagnostics development, and cell therapy manufacturing. The company’s flagship products include VisionSort (launched in 2023) and the new VisionCyte platform (pre-commercial launch in 2025), both leveraging proprietary Ghost Cytometry technology to accelerate discoveries in biology and medicine.

Therapeutic areas: OtherHematology
Modalities: DeviceNon-pharmacological therapy (cell analysis and sorting instruments)
Industry: Pathology

Partnerships

Major global biopharmaceutical companies (names undisclosed)

Beyond the preview

Go deeper on ThinkCyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ThinkCyte.

Explore the full profile